Through the collaboration, Parexel and MyEyeDr. will partner on recruitment of patients for variety of ophthalmology indications, including Macular Degeneration
Clinical Research Organisation (CRO), Parexel has announced a formal agreement with MyEyeDr. to refer its patients into existing and future ophthalmology clinical trials. Both the companies are currently collaborating on recruitment for a diabetic retinopathy clinical trial with future plans to expand into additional therapeutic areas such as endocrinology.
Through the collaboration, Parexel and MyEyeDr. will partner on recruitment of patients for variety of ophthalmology indications, including Macular Degeneration. By leveraging MyEyeDr.’s 850+ offices across 28 states, the companies will be able to disseminate information directly to the types of patients needed for ophthalmology studies with opportunities for expansion into other adjacent therapeutic areas.
Under the agreement, MyEyeDr. will be part of Parexel’s Community Alliance Network, a novel program launched in June further integrating clinical research into the community healthcare setting to better serve patients and in turn create further opportunity for increased diversity in clinical trials. MyEyeDr joins CVS Health and Javara as members of the network.
- Advertisement -